OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time

Rhea-AI Summary

OpGen, Inc. (NASDAQ: OPGN) announced a business update and first quarter 2022 financial results will be revealed on May 12, 2022. The management team will conduct a live conference call at 4:30 p.m. ET to discuss financial outcomes and ongoing business activities. The call will be accessible via U.S. and international dial-in numbers, and a webcast will be available on the company's website. OpGen specializes in precision medicine focusing on molecular diagnostics and bioinformatics to address multidrug-resistant infections.

Positive

• Scheduled financial results release on May 12, 2022, providing transparency for investors.
• Engagement with shareholders through a live conference call to discuss results.

Negative

• None.

ROCKVILLE, Md., April 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2022 financial results after the close of the U.S. financial markets on Thursday, May 12^th, 2022. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details
U.S. Dial-in Number:	1-877-704-4453
International Dial-in Number:	1-201-389-0920
Webcast:	https://services.choruscall.com/mediaframe/webcast.html?webcastid=n37Dadqy
Conference ID:	13729189

Replay Details
U.S. Dial-in Number:	1-844-512-2921
International Dial-in Number:	1-412-317-6671
Replay PIN:	13729189

Following the conclusion of the conference call, a replay will be available through May 26^th, 2022. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings.

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero^®, Acuitas^® AMR Gene Panel and the ARES Technology Platform including ARESdb^®, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Alyssa Factor
Edison Group
afactor@edisongroup.com

FAQ

What are the details of OpGen's first quarter 2022 financial results release?

OpGen will announce its first quarter 2022 financial results on May 12, 2022, after the market close.

When will OpGen's conference call take place?

The conference call will be held on May 12, 2022, at 4:30 p.m. ET.

How can investors access the OpGen conference call?

Investors can access the conference call through U.S. and international dial-in numbers or a live webcast available on OpGen's website.

What is OpGen's focus in the medical field?

OpGen focuses on precision medicine, utilizing molecular diagnostics and bioinformatics to combat infectious diseases.